These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9007411)

  • 1. Neurotoxicity of beta-amyloid and prion peptides.
    Forloni G
    Curr Opin Neurol; 1996 Dec; 9(6):492-500. PubMed ID: 9007411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid in Alzheimer's disease and prion-related encephalopathies: studies with synthetic peptides.
    Forloni G; Tagliavini F; Bugiani O; Salmona M
    Prog Neurobiol; 1996 Jul; 49(4):287-315. PubMed ID: 8888112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prion infection of mice transgenic for human APPSwe: increased accumulation of cortical formic acid extractable Abeta(1-42) and rapid scrapie disease development.
    Baier M; Apelt J; Riemer C; Gültner S; Schwarz A; Bamme T; Burwinkel M; Schliebs R
    Int J Dev Neurosci; 2008 Nov; 26(7):821-4. PubMed ID: 18662767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tauons and prions: infamous cousins?
    Novak P; Prcina M; Kontsekova E
    J Alzheimers Dis; 2011; 26(3):413-30. PubMed ID: 21694453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers.
    Ugalde CL; Finkelstein DI; Lawson VA; Hill AF
    J Neurochem; 2016 Oct; 139(2):162-180. PubMed ID: 27529376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer disease and the prion disorders amyloid beta-protein and prion protein amyloidoses.
    Price DL; Borchelt DR; Sisodia SS
    Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6381-4. PubMed ID: 8101988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of mutations associated with familial prion-related encephalopathies on biological activity of prion protein peptides.
    Forloni G; Angeretti N; Malesani P; Peressini E; Rodriguez Martin T; Della Torre P; Salmona M
    Ann Neurol; 1999 Apr; 45(4):489-94. PubMed ID: 10211473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new take on prions: preventing Alzheimer's disease.
    Hooper NM; Turner AJ
    Trends Biochem Sci; 2008 Apr; 33(4):151-5. PubMed ID: 18343669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis-mediated neurotoxicity induced by beta-amyloid and PrP fragments.
    Forloni G; Bugiani O; Tagliavini F; Salmona M
    Mol Chem Neuropathol; 1996; 28(1-3):163-71. PubMed ID: 8871955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lewy bodies in Alzheimer's disease in which the primary lesion is a mutation in the amyloid precursor protein.
    Hardy J
    Neurosci Lett; 1994 Oct; 180(2):290-1. PubMed ID: 7700596
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular basis of cerebral neurodegeneration in prion diseases.
    Tatzelt J; Schätzl HM
    FEBS J; 2007 Feb; 274(3):606-11. PubMed ID: 17288549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous amyloid seeding: revisiting the role of acetylcholinesterase in Alzheimer's disease.
    Jean L; Thomas B; Tahiri-Alaoui A; Shaw M; Vaux DJ
    PLoS One; 2007 Jul; 2(7):e652. PubMed ID: 17653279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's and prion disease as disorders of protein conformation: implications for the design of novel therapeutic approaches.
    Soto C
    J Mol Med (Berl); 1999 May; 77(5):412-8. PubMed ID: 10426190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases.
    Díaz-Nido J; Wandosell F; Avila J
    Peptides; 2002 Jul; 23(7):1323-32. PubMed ID: 12128089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Amyloidgenesis in prion disease].
    Tsuboi Y
    Brain Nerve; 2014 Jul; 66(7):849-55. PubMed ID: 24998829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical and structural studies of the prion protein polymorphism.
    Petchanikow C; Saborio GP; Anderes L; Frossard MJ; Olmedo MI; Soto C
    FEBS Lett; 2001 Dec; 509(3):451-6. PubMed ID: 11749972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype.
    Jayadev S; Nochlin D; Poorkaj P; Steinbart EJ; Mastrianni JA; Montine TJ; Ghetti B; Schellenberg GD; Bird TD; Leverenz JB
    Ann Neurol; 2011 Apr; 69(4):712-20. PubMed ID: 21416485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy.
    Nieznanska H; Bandyszewska M; Surewicz K; Zajkowski T; Surewicz WK; Nieznanski K
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2143-2153. PubMed ID: 29604335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of prion peptide structure and aggregation in toxicity and membrane binding.
    Rymer DL; Good TA
    J Neurochem; 2000 Dec; 75(6):2536-45. PubMed ID: 11080207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.